Medplus Health Services Limited

August 28, 2023

The Listing Department
BSE Limited
Phiroze Jeejebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,2015 – ongoing litigation.

Pursuant to the amendment to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 July 13, 2023.

The Management expects that these cases will likely be upheld upon ultimate resolution and will not have a material adverse effect on the Group's financial position and results of operations.

The details of such ongoing litigations of the Company are enclosed herewith as Annexure A.

Kindly take the same on your record.

For MedPlus Health Services Limited

MANOJ KUMAR SRIVASTAVA
Digitally signed by MANOJ KUMAR SRIVASTAVA
Date: 2023.08.28 15:19:47 +05'30'

Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS 7460

Annexure A

MedPlus Health Services Limited (Direct Tax)

Rs. In million

Sl.	Name of the regulatory ,opposite party, authority, court , judicial forum, government authorities	Court / tribunal / Agency where litigation is filed /pending	Period to which the dispute or litigation pertains / pending/Assessment year etc.	Brief fact of dispute / litigation	Expected financial impact, if any due to compensation / penalty	Quantum of claim if any	Present status of the case	Reference
1	Income Tax Authority	CIT(Appeals)	FY 20-21 (AY 21-22)	The Company has received Assessment order U/s-143(3) on 29/12/22 with a demand of Rs.3.48 Crores due to various adjustments like ESOP expenses, 56(2)(viib) and others made by the Department, the company has filed an Appeal with CIT(A). The hearing date is yet to be received.	34.86	N.A.	Matter Pending at CIT(A).	FY 2022-23.
Optival Health Solutions Private Limited- Subsidiary Company (Direct Tax)								
2	Income Tax Authority	CIT(Appeals)	FY 16-17 (AY 17-18)	Assessment order U/s 143(3) received by the Company disallowing depreciation on Goodwill amounting to Rs.20.81 Crores as against IT Refund claimed in the return of Rs.9.29 Crores. The Company has filed Appeal on 29/01/2020 with CIT(A) against the Assessment Order.	83.05	N.A	Matter Pending at CIT(A).	Pg. 243 of Annual Report(AR) 2021-22
3	Income Tax Authority	CIT(Appeals)	FY 19-20 (AY 20-21)	Assessment order U/s 143(3) received by the Company with a demand of Rs.43.45 Crores for an adjustment made by the Assessing Officer for Rs.132 Crores U/s 56(2)(viib), the company filed a writ petition with the Telangana High Court. The Court granted interim stay for the Assessment Order. The next date of hearing is scheduled on 29/09/2023.	434.51	N.A	Matter Pending at Hon'ble High Court.	For the year FY 2022-23.
Deccan Medisales private Limited- Subsidiary Company (Direct Tax)								
4	Income Tax Authority	CIT(Appeals)	FY 16-17 (AY 17-18)	Assessment order U/s 143(3) received by the Company with a demand of Rs.19.25 Crores towards difference in Turnover as per VAT Returns and Financials, the company filed an Appeal with CIT(A) Bangalore. Hearing done on 29/01/2020 and case is remanded back to AO. Remand report submitted by DCIT to CIT(A) with favorable comment. Final Order to be received from CIT(A).	192.54	N.A	Matter Pending at CIT (A).	Pg. 244 of Annual Report 2021-22.

Note: The company is having various other litigation / dispute pending before several government authorities / Hon'ble High court under Income Tax, GST, Service Tax, Drugs & Cosmetic Act, Essential Commodity Act etc. and other matters, which does not meet the materiality threshold therefore, not considered above.